U.S. markets close in 2 hours 16 minutes
  • S&P 500

    -1.84 (-0.05%)
  • Dow 30

    +33.70 (+0.11%)
  • Nasdaq

    -85.28 (-0.63%)
  • Russell 2000

    -26.62 (-1.17%)
  • Crude Oil

    +0.05 (+0.08%)
  • Gold

    +12.80 (+0.74%)
  • Silver

    +0.28 (+1.04%)

    +0.0031 (+0.25%)
  • 10-Yr Bond

    -0.0200 (-1.38%)

    +0.0054 (+0.39%)

    +0.0090 (+0.01%)

    -1,201.86 (-2.45%)
  • CMC Crypto 200

    -29.87 (-3.03%)
  • FTSE 100

    +25.22 (+0.38%)
  • Nikkei 225

    -255.33 (-0.86%)

Vanda Begins Enrollment in Study for Severe Coronavirus Infection

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Vanda Pharmaceuticals Inc. VNDA along with The Feinstein Institutes for Medical Research (a research arm of Northwell Health) announced that the first patient has been enrolled in the late-stage clinical study of ODYSSEY VLY-686-3501 on tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection.

Recruiment of patients is currently underway at the Lenox Hill Hospital in New York City. Vanda had earlier announced plans to conduct such a study beginning this month.

Per the company, the above-mentioned study is expected to randomize around 300 patients with severe COVID-19 infection who are suffering pneumonia and are dosed with either tradipitant or placebo. Vanda expects to accelerate enrollment in this study and announce results in the upcoming months.

Notably, the novel coronavirus (SARS-CoV-2) is associated with a lower respiratory tract inflammation that often leads to acute respiratory distress syndrome (ARDS) requiring mechanical ventilation.

We note that Vanda in-licensed tradipitant, a neurokinin-1 receptor antagonist, from pharma giant Eli Lilly LLY. The candidate is currently not approved for any indication and is being developed for gastroparesis, motion sickness and atopic dermatitis.

Shares of Vanda have plunged 36.5% so far this year compared with the industry’s decrease of 2.9%.

In a separate press release, Vanda announced that it initiated the CALYPSO program to study the role that human genetic variations play in the COVID-19 infection and disease progression. The company is looking to collaborate with the University of Washington School of Medicine to conduct a pharmacogenetics study for patients with COVID-19.

The focus of the study will be on the genome sequencing of individual patients and the COVID-19 virus besides identifying genetic factors that correlate with disease progression and outcomes.

Meanwhile, several companies are testing their marketed drugs in studies to check the inflammatory response in patients with the severe coronavirus infection.

Earlier this month, Incyte INCY announced that it is working with the FDA to initiate a phase III study, RUXCOVID, for evaluating the efficacy and safety of Jakafi plus standard-of-care compared to the standard-of-care therapy alone in patients with COVID-19-associated cytokine storm.

Others include Roche’s RHHBY rheumatoid arthritis (RA) drug Actemra and Regeneron/Sanofi’s RA drug Kevzara.

Zacks Rank

Vanda currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Incyte Corporation (INCY) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Vanda Pharmaceuticals Inc. (VNDA) : Free Stock Analysis Report
To read this article on Zacks.com click here.